Back to Search
HAGOP KANTARJIAN, MD
MD
Medical Oncology Physician
NPI: 1316020290IndividualAccepts Medicare
Specialties, Licenses & Credentials
Medical Oncology PhysicianPrimary
Internal Medicine — Medical Oncology
Code: 207RX0202X
G5239(TX)
Education
OTHER
Class of 1979
Research & Publications (20)
Imatinib mesylate therapy for polycythemia vera: final result of a phase II study initiated in 2001.
PMID 19484334·Int J Hematol·2009
3-trial
Significance of increasing levels of minimal residual disease in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in complete cytogenetic response.
PMID 19487383·J Clin Oncol·2009
4-observational
Mutation profile of JAK2 transcripts in patients with chronic myeloproliferative neoplasias.
PMID 19074595·J Mol Diagn·2009
8-other
Efficacy of imatinib dose escalation in patients with chronic myeloid leukemia in chronic phase.
PMID 19117345·Cancer·2009
8-other
Incidence of extramedullary disease in patients with acute promyelocytic leukemia: a single-institution experience.
PMID 19340529·Int J Hematol·2009
8-other
Dasatinib or high-dose imatinib for chronic-phase chronic myeloid leukemia resistant to imatinib at a dose of 400 to 600 milligrams daily: two-year follow-up of a randomized phase 2 study (START-R).
PMID 19536906·Cancer·2009
3-trial
Introduction: targeting different pathways to prevent tumor cell development.
PMID 19393830·Semin Oncol·2009
8-other
Phase 3 study of dasatinib 140 mg once daily versus 70 mg twice daily in patients with chronic myeloid leukemia in accelerated phase resistant or intolerant to imatinib: 15-month median follow-up.
PMID 19369231·Blood·2009
3-trial
Therapeutic advances in leukemia and myelodysplastic syndrome over the past 40 years.
PMID 18798533·Cancer·2008
6-review
Cytogenetic and molecular responses and outcome in chronic myelogenous leukemia: need for new response definitions?
PMID 18085610·Cancer·2008
8-other
Monitoring the response and course of chronic myeloid leukemia in the modern era of BCR-ABL tyrosine kinase inhibitors: practical advice on the use and interpretation of monitoring methods.
PMID 18055868·Blood·2008
6-review
BCR-ABL tyrosine kinase inhibitors in chronic myeloid leukemia: using guidelines to make rational treatment choices.
PMID 18397680·J Natl Compr Canc Netw·2008
6-review
Proposal for a new risk model in myelodysplastic syndrome that accounts for events not considered in the original International Prognostic Scoring System.
PMID 18618511·Cancer·2008
8-other
Diagnosis and management of chronic myeloid leukemia: a survey of American and European practice patterns.
PMID 17326047·Cancer·2007
5-case
Outcome of patients with Philadelphia chromosome-positive chronic myelogenous leukemia post-imatinib mesylate failure.
PMID 17342766·Cancer·2007
8-other
The incidence and impact of thrombocytopenia in myelodysplastic syndromes.
PMID 17366593·Cancer·2007
6-review
Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance.
PMID 17715389·Blood·2007
3-trial
Purine Nucleosidase Phosphorylase (PNP): A novel target in leukemias and lymphomas.
PMID 18086341·Semin Oncol·2007
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 1515 HOLCOMBE BLVD, 77030-4009
HOUSTON, TX 77030 - Phone
- (713) 792-6161
Quick Facts
- NPI
- 1316020290
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Accepted
- Specialties
- 1
- Locations
- 1
- Years in Practice
- 47
- Publications
- 20
Are you this provider?
Claim Your Profile